Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Martina Biggioggero, Chiara Crotti, Andrea Becciolini & Ennio Giulio Favalli. (2019) Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Design, Development and Therapy 13, pages 57-70.
Read now
Read now
Maria Soledad Ormaechea, Muhammad Hassan, Neil Onghanseng, Jung Hyun Park, Sarakshi Mahajan, Khalid Yusuf Al-Kirwi, Gunay Uludag, Muhammad Sohail Halim, Ariel Schlaen, Yasir J Sepah, Diana V Do & Quan Dong Nguyen. (2019) Safety of systemic therapy for noninfectious uveitis. Expert Opinion on Drug Safety 18:12, pages 1219-1235.
Read now
Read now
Atsushi Ogata, Yoshiya Tanaka, Tomonori Ishii, Motohide Kaneko, Hiroko Miwa, Shino Ohsawa & Reiji Yamakawa. (2019) Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. Modern Rheumatology 29:5, pages 767-774.
Read now
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Read now
Maria Gabriella Raimondo, Martina Biggioggero, Chiara Crotti, Andrea Becciolini & Ennio Giulio Favalli. (2017) Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy 11, pages 1593-1603.
Read now
Read now
Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi & Bhaskar Dasgupta. (2017) Tocilizumab (Actemra). Human Vaccines & Immunotherapeutics 13:9, pages 1972-1988.
Read now
Read now
Naoki Ishiguro, Tatsuya Atsumi, Masayoshi Harigai, Tsuneyo Mimori, Norihiro Nishimoto, Takayuki Sumida, Tsutomu Takeuchi, Yoshiya Tanaka, Ayako Nakasone, Nobuhiro Takagi & Hisashi Yamanaka. (2017) Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology 27:2, pages 217-226.
Read now
Read now
Özgül Muştu Koryürek & Göknur Kalkan. (2016) A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 35:2, pages 145-152.
Read now
Read now
Tomomi Tsuru, Kimio Terao, Miho Murakami, Takaji Matsutani, Midori Suzaki, Toshiaki Amamoto, Hitoshi Nakashima, Azusa Akiyama & Norihiro Nishimoto. (2014) Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Modern Rheumatology 24:3, pages 511-516.
Read now
Read now
Yasuharu Nakashima, Masakazu Kondo, Takaaki Fukuda, Hiroshi Harada, Takahiko Horiuchi, Takashi Ishinishi, Hiroshi Jojima, Koji Kuroda, Hisaaki Miyahara, Masayuki Maekawa, Hiroaki Nishizaka, Ryuji Nagamine, Hitoshi Nakashima, Takeshi Otsuka, Eisuke Shono, Eiichi Suematsu, Takashi Shimauchi, Tomomi Tsuru, Ken Wada, Shigeru Yoshizawa, Seiji Yoshizawa & Yukihide Iwamoto. (2014) Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. Modern Rheumatology 24:2, pages 258-264.
Read now
Read now
Trung N Tran, Herve Caspard & Fabio Magrini. (2013) Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis – a systematic evaluation of the literature. Open Access Rheumatology: Research and Reviews 5, pages 21-32.
Read now
Read now
Y Hishitani, A Ogata, Y Shima, T Hirano, K Ebina, Y Kunugiza, K Shi, M Narazaki, K Hagihara, T Tomita, H Yoshikawa, T Tanaka & A Kumanogoh. (2013) Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology 42:4, pages 253-259.
Read now
Read now
Louisa Voight. (2012) Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns. Patient Preference and Adherence 6, pages 275-283.
Read now
Read now
Zoe Ash & Paul Emery. (2012) The role of tocilizumab in the management of rheumatoid arthritis. Expert Opinion on Biological Therapy 12:9, pages 1277-1289.
Read now
Read now
Michel Vierboom, Elia Breedveld & Bert A ‘t Hart. (2012) New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis. Expert Opinion on Drug Discovery 7:4, pages 315-325.
Read now
Read now
Masahiko Mihara, Yoshiyuki Ohsugi & Tadamitsu Kishimoto. (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatology: Research and Reviews 3, pages 19-29.
Read now
Read now
Ithamar Heber Brinkman, Mart AFJ van de Laar, Tim L Jansen & Eric N van Roon. (2011) The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. Expert Opinion on Drug Safety 10:5, pages 715-726.
Read now
Read now
Bernard Bannwarth & Christophe Richez. (2011) Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opinion on Drug Safety 10:1, pages 123-131.
Read now
Read now
Toshio Tanaka, Atsushi Ogata & Masashi Narazaki. (2010) Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 6:6, pages 843-854.
Read now
Read now
Articles from other publishers (80)
Jiahui Yan, Sisi Yang, Liang Han, Xin Ba, Pan Shen, Weiji Lin, Tingting Li, Ruiyuan Zhang, Ying Huang, Yao Huang, Kai Qin, Yu Wang, Shenghao Tu & Zhe Chen. (2023) Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Frontiers in Immunology 14.
Crossref
Crossref
Masataka Kuwana, Naonobu Sugiyama, Shigeki Momohara, Tatsuya Atsumi, Syuji Takei, Naoto Tamura, Masayoshi Harigai, Takao Fujii, Hiroaki Matsuno, Tsutomu Takeuchi, Kazuhiko Yamamoto, Yoshinari Takasaki, Miki Tanigawa, Yutaka Endo, Tomohiro Hirose, Yosuke Morishima, Noritoshi Yoshii, Tsuneyo Mimori & Michiaki Takagi. (2023) Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. Modern Rheumatology.
Crossref
Crossref
Luca Muzio, Alma Ghirelli, Federica Agosta & Gianvito Martino. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
523
537
.
Akito Ohkubo, Takashi Osoegawa, Naohiko Harada, Yoichiro Iboshi, Yorinobu Sumida, Makoto Nakamuta, Eiichi Suematsu, Hiroyuki Kobayashi & Eikichi Ihara. (2022) A Rare Case of Rheumatoid Arthritis with Tocilizumab-induced Intestinal Mucosal Injury. Internal Medicine 61:7, pages 1011-1014.
Crossref
Crossref
Luca MASTORINO, Gianluca AVALLONE, Paolo DAPAVO, Martina MERLI, Andrea AGOSTINI, Damiano GRANDINETTI, Maria T. FIERRO, Pietro QUAGLINO & Simone RIBERO. (2022) Tocilizumab and its usage for skin diseases. Italian Journal of Dermatology and Venereology 157:1.
Crossref
Crossref
Ronald Man Lung Yip & Cheuk Wan Yim. (2021) Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. JCR: Journal of Clinical Rheumatology 27:8, pages e516-e524.
Crossref
Crossref
Ha-Lim Jeon, Seoyoung C. Kim, So-Hee Park & Ju-Young Shin. (2021) The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. Seminars in Arthritis and Rheumatism 51:5, pages 989-995.
Crossref
Crossref
Anthony P. Longhitano, Monica A. Slavin, Simon J. Harrison & Benjamin W. Teh. (2021) Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Reviews 49, pages 100810.
Crossref
Crossref
Xue Wu, Meng Sun, Zhi Yang, Chenxi Lu, Qiang Wang, Haiying Wang, Chao Deng, Yonglin Liu & Yang Yang. (2021) The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Ruth Davies, Jessica Williams, Katie Sime, Hyun-Sun Jin, Charlotte Thompson, Lauren Jordan, Derek Lang, Julian P Halcox, Elizabeth Ellins, Gareth W Jones, Simon A Jones, Stefan Rose-John, Anwen Williams & Ernest Choy. (2021) The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60:6, pages 2852-2861.
Crossref
Crossref
Hojjat Naseri, Rasoul Zarrin, Parvin Ayremlou, Mir Amir Aghdashi & Seyedmostafa Seyedmardani. (2020) Evaluating the relationship between dietary intake with inflammatory factors, lipid profile and clinical symptoms in patients with rheumatoid arthritis. Clinical Nutrition ESPEN 40, pages 138-143.
Crossref
Crossref
Brandon Huy Pham, Doan Luong Hien, Wataru Matsumiya, Than Trong Tuong Ngoc, Huy Luong Doan, Amir Akhavanrezayat, Çigdem Yaşar, Huy Vu Nguyen, Muhammad Sohail Halim & Quan Dong Nguyen. (2020) Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema. American Journal of Ophthalmology Case Reports 20, pages 100881.
Crossref
Crossref
Luca Bernardo, Stefania Del Sesto, Laura Giordano, Anna Rita Benincaso, Piero Biondi, Vinicio Goj, Francesca Ferrara, Antonella Talenti, Antonella Grisolia & Paolo Antonio Ascierto. (2020) Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature. Drugs & Therapy Perspectives 36:12, pages 568-572.
Crossref
Crossref
Sajad Khiali, Elnaz Khani & Taher Entezari‐Maleki. (2020) A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome. The Journal of Clinical Pharmacology 60:9, pages 1131-1146.
Crossref
Crossref
Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, Réjean Lapointe, Marie Hudson, Bertrand Routy, Wilson H. MillerJrJr & Leonard Calabrese. (2020) Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology 17:8, pages 504-515.
Crossref
Crossref
Anne Y. Liu. (2020) Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. Infectious Disease Clinics of North America 34:2, pages 211-234.
Crossref
Crossref
Zengshu Huang, Jing Zhou, Wing Ting Leung, Hans Jürgen Gober, Xinyao Pan, Chuyu Li, Lisha Li & Ling Wang. (2020) The novel role of Hippo-YAP/TAZ in immunity at the mammalian maternal-fetal interface: Opportunities, challenges. Biomedicine & Pharmacotherapy 126, pages 110061.
Crossref
Crossref
Andrew N. Wilkinson, Karshing ChangRachel D. KunsAndrea S. Henden, Simone A. MinnieKathleen S. EnsbeyAndrew D. CloustonPing Zhang, Motoko KoyamaJuan Hidalgo, Stefan Rose-John, Antiopi Varelias, Slavica VuckovicKate H. Gartlan & Geoffrey R. Hill. (2019) IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood 134:23, pages 2092-2106.
Crossref
Crossref
Vanesa Viana-Huete & José J. Fuster. (2019) Valor terapéutico potencial de las estrategias dirigidas contra la interleucina 1β en la enfermedad cardiovascular ateroesclerótica. Revista Española de Cardiología 72:9, pages 760-766.
Crossref
Crossref
Vanesa Viana-Huete & José J. Fuster. (2019) Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease. Revista Española de Cardiología (English Edition) 72:9, pages 760-766.
Crossref
Crossref
Vivian P. Bykerk, Andrew J. K. Östör, José Alvaro-Gracia, Karel Pavelka, José Andrés Román Ivorra, Michael T. Nurmohamed, Yves Luder, Paris N. M. Sidiropoulos, Jenny Devenport & Jean Sibilia. (2019) Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. Clinical Rheumatology 38:9, pages 2411-2421.
Crossref
Crossref
Sujin Kang, Toshio Tanaka, Masashi Narazaki & Tadamitsu Kishimoto. (2019) Targeting Interleukin-6 Signaling in Clinic. Immunity 50:4, pages 1007-1023.
Crossref
Crossref
Christopher R Holroyd, Rakhi Seth, Marwan Bukhari, Anshuman Malaviya, Claire Holmes, Elizabeth Curtis, Christopher Chan, Mohammed A Yusuf, Anna Litwic, Susan Smolen, Joanne Topliffe, Sarah Bennett, Jennifer Humphreys, Muriel Green & Jo Ledingham. (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 58:2, pages e3-e42.
Crossref
Crossref
春娇 潘. (2019) A IL-6 Receptor Blocker for Rheumatoid Ar-thritis—Sarilumab. Pharmacy Information 08:01, pages 1-8.
Crossref
Crossref
Diederik De Cock & Kimme Hyrich. (2018) Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Practice & Research Clinical Rheumatology 32:6, pages 869-886.
Crossref
Crossref
Masashi Narazaki & Tadamitsu Kishimoto. (2018) The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences 19:11, pages 3528.
Crossref
Crossref
Vincent J. Mariano & William H. Frishman. (2018) Tocilizumab in Giant Cell Arteritis. Cardiology in Review 26:6, pages 321-330.
Crossref
Crossref
Tianxi Cai, Yichi Zhang, Yuk-Lam Ho, Nicholas Link, Jiehuan Sun, Jie Huang, Tianrun A. Cai, Scott Damrauer, Yuri Ahuja, Jacqueline Honerlaw, Jie Huang, Lauren Costa, Petra Schubert, Chuan Hong, David Gagnon, Yan V. Sun, J. Michael Gaziano, Peter Wilson, Kelly Cho, Philip Tsao, Christopher J. O’Donnell & Katherine P. Liao. (2018) Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy. JAMA Cardiology 3:9, pages 849.
Crossref
Crossref
Andrew N. Wilkinson, Kate H. Gartlan, Greg Kelly, Luke D. Samson, Stuart D. Olver, Judy Avery, Nienke Zomerdijk, Siok-Keen Tey, Jason S. Lee, Slavica Vuckovic & Geoffrey R. Hill. (2018) Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130. The Journal of Immunology 200:10, pages 3547-3555.
Crossref
Crossref
Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei, Yoshiya Tanaka, Tomonori Ishii, Shumpei Yokota, Akira Nomura, Seitaro Yoshida & Norihiro Nishimoto. (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases 77:3, pages 348-354.
Crossref
Crossref
Hiroaki Nishioka, Hiroshi Takegawa & Hiroki Kamei. (2018) Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease. Journal of Infection and Chemotherapy 24:2, pages 138-141.
Crossref
Crossref
Yasir Jamal Sepah, Mohammad Ali Sadiq, David S. Chu, Mark Dacey, Ron Gallemore, Pouya Dayani, Mostafa Hanout, Muhammad Hassan, Rubbia Afridi, Aniruddha Agarwal, Muhammad Sohail Halim, Diana V. Do & Quan Dong Nguyen. (2017) Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. American Journal of Ophthalmology 183, pages 71-80.
Crossref
Crossref
Lesley J. Scott. (2017) Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 77:17, pages 1865-1879.
Crossref
Crossref
Jacques Morel, Arnaud Constantin, Gabriel Baron, Emmanuelle Dernis, René Marc Flipo, Stéphanie Rist, Bernard Combe, Jacques Eric Gottenberg, Thierry Schaeverbeke, Martin Soubrier, Olivier Vittecoq, Maxime Dougados, Alain Saraux, Xavier Mariette, Philippe Ravaud & Jean Sibilia. (2017) Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology 56:10, pages 1746-1754.
Crossref
Crossref
Rosario García-Vicuña, María Auxiliadora Martín-Martínez, María Rosa Gonzalez-Crespo, Jesús Tornero-Molina, Antonio Fernández-Nebro, Francisco Javier Blanco-García, Ricardo Blanco-Alonso & Sara Marsal-Barril. (2017) Recommendations by the Spanish Rheumatology Society for the Management of Patients Diagnosed With Rheumatoid Arthritis who Cannot Be Treated With Methotrexate. Reumatología Clínica (English Edition) 13:3, pages 127-138.
Crossref
Crossref
Rosario García-Vicuña, María Auxiliadora Martín-Martínez, María Rosa Gonzalez-Crespo, Jesús Tornero-Molina, Antonio Fernández-Nebro, Francisco Javier Blanco-García, Ricardo Blanco-Alonso & Sara Marsal-Barril. (2017) Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato. Reumatología Clínica 13:3, pages 127-138.
Crossref
Crossref
Andrew Rutherford, Elena Nikiphorou & James Galloway. 2017. Comorbidity in Rheumatic Diseases. Comorbidity in Rheumatic Diseases
53
79
.
Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose & Samuel Zwillich. (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Yuko Kaneko, Tatsuya Atsumi, Yoshiya Tanaka, Masayuki Inoo, Hitomi Kobayashi-Haraoka, Koichi Amano, Masayuki Miyata, Yohko Murakawa, Hidekata Yasuoka, Shintaro Hirata, Hayato Nagasawa, Eiichi Tanaka, Nobuyuki Miyasaka, Hisashi Yamanaka, Kazuhiko Yamamoto & Tsutomu Takeuchi. (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Annals of the Rheumatic Diseases 75:11, pages 1917-1923.
Crossref
Crossref
Franck Patin, Thomas Baranek, Patrick Vourc’h, Lydie Nadal-Desbarats, Jean-François Goossens, Sylviane Marouillat, Anne-Frédérique Dessein, Amandine Descat, Blandine Madji Hounoum, Clément Bruno, Hervé Watier, Mustafa Si-Tahar, Samuel Leman, Jean-Claude Lecron, Christian R. Andres, Philippe Corcia & Hélène Blasco. (2016) Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. Neurotherapeutics 13:4, pages 905-917.
Crossref
Crossref
Kunihiro Yamaoka. (2016) Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. Drug Safety 39:9, pages 823-840.
Crossref
Crossref
Su-Ann Yeoh, Christine Fox & Richard Hull. (2016) Neutropenia in the Elderly: A Rheumatology Perspective. Drugs & Aging 33:8, pages 585-601.
Crossref
Crossref
Gerhard W. Naerr, Philipp Rein, Christoph H. Saely & Heinz Drexel. (2016) Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascular Pharmacology 81, pages 22-30.
Crossref
Crossref
Timo Gaber, Martin Hahne, Cindy Strehl, Paula Hoff, Yvonne Dörffel, Eugen Feist, Gerd-Rüdiger Burmester & Frank Buttgereit. (2015) Disentangling the effects of tocilizumab on neutrophil survival and function. Immunologic Research 64:3, pages 665-676.
Crossref
Crossref
Xiang-nan Jin, En-zhi Yan, Han-ming Wang, Hai-juan Sui, Zhou Liu, Wei Gao & Ying Jin. (2016) Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. Acta Pharmacologica Sinica 37:5, pages 674-686.
Crossref
Crossref
Ryoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka & Masayoshi Harigai. (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Kostas Athanasakis, Filippos Tarantilis, Konstantina Tsalapati, Thomais Konstantopoulou, Eleni Vritzali & John Kyriopoulos. (2015) Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatology International 35:9, pages 1489-1495.
Crossref
Crossref
Jochen Dutzmann, Jan-Marcus Daniel, Johann Bauersachs, Denise Hilfiker-Kleiner & Daniel G. Sedding. (2015) Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovascular Research 106:3, pages 365-374.
Crossref
Crossref
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Claiton Viegas Brenol, Daniel Feldman Pollak, Geraldo da Rocha Castelar Pinheiro, Ieda Maria Magalhães Laurindo, Ivânio Alves Pereira, Jozélio Freire de Carvalho, Manoel Barros Bertolo, Marcelo de Medeiros Pinheiro, Max Victor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Júnior, Percival Degrava Sampaio-Barros, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima & Luis Eduardo Coelho Andrade. (2015) Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides. Revista Brasileira de Reumatologia (English Edition) 55:3, pages 281-309.
Crossref
Crossref
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Claiton Viegas Brenol, Daniel Feldman Pollak, Geraldo da Rocha Castelar Pinheiro, Ieda Maria Magalhães Laurindo, Ivânio Alves Pereira, Jozélio Freire de Carvalho, Manoel Barros Bertolo, Marcelo de Medeiros Pinheiro, Max Victor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada‐Júnior, Percival Degrava Sampaio‐Barros, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima & Luis Eduardo Coelho Andrade. (2015) Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia 55:3, pages 281-309.
Crossref
Crossref
Rosario Peluso, Francesco Manguso, Maria Vitiello, Salvatore Iervolino & Matteo Nicola Dario Di Minno. (2014) Management of arthropathy in inflammatory bowel diseases. Therapeutic Advances in Chronic Disease 6:2, pages 65-77.
Crossref
Crossref
O. Shovman, Y. Shoenfeld & P. Langevitz. (2014) Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. Immunologic Research 61:1-2, pages 164-168.
Crossref
Crossref
Tomas Söderman, Claes Olerud, Adel Shalabi, Kamran Alavi & Anders Sundin. (2014) Static and dynamic CT imaging of the cervical spine in patients with rheumatoid arthritis. Skeletal Radiology 44:2, pages 241-248.
Crossref
Crossref
Alejandro Souto, Eva Salgado, Jos? Ram?n Maneiro, Antonio Mera, Loreto Carmona & Juan J. G?mez-Reino. (2015) Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. Arthritis & Rheumatology 67:1, pages 117-127.
Crossref
Crossref
Waka Yokoyama, Hitoshi Kohsaka, Kayoko Kaneko, Matthew Walters, Aiko Takayasu, Shin Fukuda, Chie Miyabe, Yoshishige Miyabe, Paul E Love, Nobuhiro Nakamoto, Takanori Kanai, Kaori Watanabe-Imai, Trevor T Charvat, Mark ET Penfold, Juan Jaen, Thomas J Schall, Masayoshi Harigai, Nobuyuki Miyasaka & Toshihiro Nanki. (2014) Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Research & Therapy 16:5.
Crossref
Crossref
Cheng Zhang, Xi Zhang & Xing-Hua Chen. (2014) Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance. Clinical Reviews in Allergy & Immunology 47:2, pages 163-173.
Crossref
Crossref
Dinny Wallis. (2014) Infection risk and biologics. Current Opinion in Rheumatology 26:4, pages 404-409.
Crossref
Crossref
Oscar Epis, Emilio Filippucci, Andrea Delle Sedie, Anna De Matthaeis & Eleonora Bruschi. (2013) Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series. Rheumatology International 34:5, pages 737-742.
Crossref
Crossref
Sohita Dhillon. (2013) Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis. BioDrugs 28:1, pages 75-106.
Crossref
Crossref
Shuji Ohta, Tomomi Tsuru, Kimio Terao, Seiji Mogi, Midori Suzaki, Eisuke Shono, Yoshimasa Ishida, Eriko Tarumi & Masato Imai. (2013) Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). The Journal of Clinical Pharmacology 54:1, pages 109-119.
Crossref
Crossref
Jutatip Guptarak, Sheshali Wanchoo, Julieann Durham-Lee, Yewen Wu, Dragoslava Zivadinovic, Adriana Paulucci-Holthauzen & Olivera Nesic. (2013) Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain 154:7, pages 1115-1128.
Crossref
Crossref
Janna A. van Diepen, Jimmy F.P. Berb?e, Louis M. Havekes & Patrick C.N. Rensen. (2013) Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 228:2, pages 306-315.
Crossref
Crossref
Medha Barbhaiya & Daniel H. Solomon. (2013) Rheumatoid arthritis and cardiovascular disease. Current Opinion in Rheumatology 25:3, pages 317-324.
Crossref
Crossref
Toshio Tanaka, Atsushi OgataMasashi Narazaki. (2013) Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Clinical Medicine Insights: Therapeutics 5, pages CMT.S9282.
Crossref
Crossref
Jin Ha LeeJae Hee Cheon. (2013) Natural Course of Crohn's Disease and Novel Treatment Drugs. Korean Journal of Medicine 85:6, pages 578.
Crossref
Crossref
Atsushi Kaneko. (2013) Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Therapeutic Advances in Chronic Disease 4:1, pages 15-21.
Crossref
Crossref
Michael Drepper, Laura Rubbia-Brandt & Laurent Spahr. (2013) Tocilizumab-Induced Acute Liver Injury in Adult Onset Still’s Disease. Case Reports in Hepatology 2013, pages 1-3.
Crossref
Crossref
Rachel Byng-Maddick & Michael Ehrenstein. (2012) Infections in biological agents used in rheumatic disease. British Journal of Hospital Medicine 73:9, pages 517-520.
Crossref
Crossref
Jean‐Frédéric Boyer, Vanina Bongard, Alain Cantagrel, Bénédicte Jamard, Jacques‐Eric Gottenberg, Xavier Mariette, Jean‐luc Davignon, Jean Ferrières, Jean‐Bernard Ruidavets, Jean Dallongeville, Dominique Arveiler, Anne Cambon‐Thomsen & Arnaud Constantin. (2012) Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort. Arthritis Care & Research 64:6, pages 872-880.
Crossref
Crossref
Veronika R. Lang, Matthias Englbrecht, J?rgen Rech, Hubert N?sslein, Karin Manger, Florian Schuch, Hans-Peter Tony, Martin Fleck, Bernhard Manger, Georg Schett & Jochen Zwerina. (2012) Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology 51:5, pages 852-857.
Crossref
Crossref
C.I. Daïen & P. Fesler. (2012) La polyarthrite rhumatoïde : une maladie cardiovasculaire ?. Annales de Cardiologie et d'Angéiologie 61:2, pages 111-117.
Crossref
Crossref
. (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet 379:9822, pages 1214-1224.
Crossref
Crossref
Atsushi OgataToru HiranoYoshihiro HishitaniToshio Tanaka. (2012) Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 5, pages CMAMD.S7371.
Crossref
Crossref
Jeffrey D. Greenberg, Victoria Furer & Michael E. Farkouh. (2011) Cardiovascular safety of biologic therapies for the treatment of RA. Nature Reviews Rheumatology 8:1, pages 13-21.
Crossref
Crossref
Kenji Okumura, Fumihiro Shoji, Masaki Yoshida, Atsushi Mizuta, Ichiro Makino & Hidefumi Higashi. (2011) Severe sepsis caused by Aeromonas hydrophila in a patient using tocilizumab: a case report. Journal of Medical Case Reports 5:1.
Crossref
Crossref
Toshio Tanaka, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata & Atsushi Kumanogoh. (2011) Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders. Drug Development Research 72:8, pages 717-732.
Crossref
Crossref
Robert S. Woodrick & Eric M. Ruderman. (2011) Safety of biologic therapy in rheumatoid arthritis. Nature Reviews Rheumatology 7:11, pages 639-652.
Crossref
Crossref
Catuxa Prado, Banesa de Paz, Jesús Gómez, Patricia López, Javier Rodríguez-Carrio & Ana Suárez. (2011) Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients. Rheumatology 50:10, pages 1794-1801.
Crossref
Crossref
AN Malaviya & Nigil Haroon. (2011) Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal. Indian Journal of Rheumatology 6:1, pages 99-112.
Crossref
Crossref
Masakatsu Yanagimachi, Takuya Naruto, Takuma Hara, Masako Kikuchi, Ryoki Hara, Takako Miyamae, Tomoyuki Imagawa, Masaaki Mori, Tetsuji Kaneko, Satoshi Morita, Hiroaki Goto & Shumpei Yokota. (2011) Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. British Journal of Clinical Pharmacology 71:2, pages 237-243.
Crossref
Crossref